Markets:

Overview

News

Currencies

International

Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

11.78 +0.42 (+3.70%)

Streaming Delayed Price Updated: 10:44 AM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma

November 15, 2021

From Novocure

Via Business Wire

Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting

November 15, 2021

From Novocure

Via Business Wire

What's the Outlook for Novocure? ↗

November 13, 2021

There's a lot riding on clinical studies of the company's tumor treating fields product.

Via The Motley Fool

Recap: NovoCure Q3 Earnings ↗

October 28, 2021

NovoCure (NASDAQ:NVCR) reported its Q3 earnings results on Thursday, October 28, 2021 at 06:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Earnings Scheduled For October 28, 2021 ↗

October 28, 2021

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •...

Via Benzinga

3 Healthcare Stocks That Could Be Turkeys in November ↗

October 29, 2021

You might want to avoid stuffing your portfolio with them.

Via The Motley Fool

NovoCure (NVCR) Q3 2021 Earnings Call Transcript ↗

October 28, 2021

NVCR earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

No Negative Reaction ↗

October 28, 2021

Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today.

Via Talk Markets

Why NovoCure Stock Is Sinking This Week ↗

October 28, 2021

Investors weren't happy with the company's Q3 update.

Via The Motley Fool

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗

October 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...

Via Benzinga

Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update

October 28, 2021

From Novocure

Via Business Wire

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer

October 28, 2021

From Novocure

Via Business Wire

Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting

October 21, 2021

From Novocure

Via Business Wire

Bitcoin Futures Arrive ↗

October 19, 2021

Today you can finally hold Bitcoins via an exchange-traded fund.

Via Talk Markets

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗

October 24, 2021

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...

Via Benzinga

More Chinese Trouble ↗

October 14, 2021

A day after the consumer price rise there was another price rise for producer markets.

Via Talk Markets

This Unstoppable Cancer-Treatment Company's Stock Is on Sale Now ↗

October 14, 2021

Novocure's stock keeps sliding, but the company continues to perform.

Via The Motley Fool

This Company's Device is Becoming Essential to Cancer Treatment -- Why Is the Stock Slumping? ↗

October 12, 2021

Is it time to buy this stock nearly at its 52 week low?

Via The Motley Fool

Cramer Likes Ford, But Suggests Waiting For Dips To Buy These Stocks ↗

October 11, 2021

On Friday's "Mad Money Lightning ...

Via Benzinga

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

October 04, 2021

From Novocure

Via Business Wire

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

Novocure to Report Third Quarter 2021 Financial Results

October 04, 2021

From Novocure

Via Business Wire

Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer ↗

September 14, 2021

Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating...

Via Benzinga

Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer

September 14, 2021

From Novocure

Via Business Wire

Pressure Day ↗

September 13, 2021

Today a recovery came to markets with a particular impact on uranium shares.

Via Talk Markets

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout ↗

September 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE...

Via Benzinga

A Weak Week ↗

September 10, 2021

Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants.

Via Talk Markets

Delta Variant Fears Continue ↗

September 09, 2021

The jobless level fell to 310,000 whereas the consensus forecast was for 335,000, so risks of inflation are higher.

Via Talk Markets

This Promising Healthcare Stock Is Down 50% From Its Highs; Should You Buy the Dip? ↗

September 09, 2021

Novocure has been fantastic for investors, up over 1,600% in the past five years. But in the past six months, shareholders have been on a roller coaster.

Via The Motley Fool

FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer

September 09, 2021

From Novocure

Via Business Wire

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.